Publications by authors named "N Graves"
Background: Palliative surgery reduces debilitating symptoms attributable to cancer, and the intent is to improve health-related quality of life. Malignant bowel obstruction is a common indication. Despite positive clinical outcomes, there is a shortage of economic evaluation evidence to support wider adoption of palliative surgery.
View Article and Find Full Text PDFArticle Synopsis
- Trastuzumab (Herceptin) can be given either intravenously (IV) or subcutaneously, and while both have similar effects and safety, their costs differ, especially between outpatient and homecare settings.
- The study aimed to analyze the costs associated with Homecare SC Herceptin compared to IV Herceptin administered in outpatient facilities in Singapore.
- Results showed that Homecare SC Herceptin significantly reduced annual patient costs by about 58-60%, with drug costs being the main driver; thus, switching to Homecare SC Herceptin is financially advantageous.
Cost-effectiveness of a short-course antibiotic treatment strategy for the treatment of ventilator-associated pneumonia: an economic analysis of the REGARD-VAP trial.
Lancet Glob Health
December 2024
Background: The REGARD-VAP trial showed that individualised shortened antibiotic therapy was non-inferior to usual care for mortality and pneumonia recurrence in patients with ventilator-associated pneumonia (VAP). We aimed to assess the cost-effectiveness of an individualised shortened antibiotic therapy approach in this planned economic analysis.
Methods: REGARD-VAP was a phase 4, multicentre, open-label, randomised trial to assess a short-course antibiotic treatment strategy for treatment of VAP.
The burden of healthcare-associated infections in New Zealand public hospitals 2021.
Infect Control Hosp Epidemiol
October 2024
Article Synopsis
- - The study estimates the economic and health burden of healthcare-associated infections (HAIs) in New Zealand public hospitals, revealing a 4.74% incidence rate which led to 24,191 HAIs in 2021, resulting in substantial health impacts including 76,861 lost bed days and 699 deaths.
- - The total economic burden of HAIs in 2021 reached NZ$955 million, broken down into costs for lost bed days (NZ$121 million), years of life lost (NZ$792 million), and Accident Compensation Commission claims (NZ$43 million).
- - The findings highlight the significant impact of HAIs on patients and the health system, suggesting a need for a strategic plan to implement preventive
Objectives: We used a multi-state model, which mitigates time-dependent bias, to estimate the mortality, length of stay (LOS), and costs of methicillin-resistant (MRSA) infections in Singapore.
Methods: We conducted a retrospective study in a hospital in Singapore from 2018 to 2022. Patients with MRSA infections were matched 1:1:3 to patients with MRSA colonization and patients without MRSA by age, gender, specialty, and intensive care admission, respectively.